louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01823757: Pharmaceutical Care in VA Nursing Home
Official title: The Impacts of Pharmaceutical Cares on the Elderly in a VA Nursing Home.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Focus on the Elderly in a Nursing Home
Keywords: elderly
potential inappropriate medications
pharmaceutical care
quality of life
medical expenditure
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2013-04-04
Enrollment: 100
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Resident from a Veteran nursing home and willing to receive the pharmaceutical care by pharmacists.

Brief summary: This study investigates the effect of pharmaceutical care on a Veteran nursing home. 100 patients will be selected into this controlled study.The hypothesis are:

1. After patients receive pharmaceutical care, their drug related problems will be decreased.
2. After patients received pharmaceutical care, their self-reported medical expenditure will be decreased.

Detailed description: Around 200 residents in a Veteran nursing home will be selected for reviewing inclusion and exclusion criteria. A total of 100 subjected are selected into this randomized controlled trial. Each group will have 50 subjects and then divides into 4 subgroup, according to their drug items used (5-7 and over 8 items used).

The inclusion criteria:

1. Residents of the Veteran nursing home.
2. over 65 years old.
3. complete comprehensive geriatric assessment (CGA)
4. prescription drugs more than 4 times/day, excluding stat order.
5. with 2 or more chronic diseases.

Exclusion criteria:

1. residents who were in the pharmaceutical care project of Taiwan Pharmacists Association.

Eligibility criteria: Inclusion Criteria:

* Residents in the Veteran nursing home
* Age over 65 years old
* Complete Comprehensive Geriatric Assessment (CGA)
* Use more than 4 drug item per day (excluding stat order)
* subjects with more than 2 chronic diseases.

Exclusion Criteria:

* subjects who were in pharmaceutical care project of Taiwan Pharmacist Association.

Primary outcomes:
measure: potential inappropriate medication (PIA)
timeFrame: one year
Secondary outcomes:
measure: drug items used
timeFrame: one year
measure: medical expenditure
timeFrame: one year
Other outcomes:
measure: quality of life measure
timeFrame: one year
Locations:
city: Changhua City
country: Taiwan
facility: Changhua Domiciliar Center
Study officials:
affiliation: Taichung Veteran General Hospital
name: Wen-Shyong Liou, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04258657: Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer
Official title: Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Gastric Cancer
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2020-02-06
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a interventional clinical trial to assess the efficacy and safety of combinational therapy of paclitaxel-albumin and S-1 for the neoadjuvant chemotherapy of advanced gastric cancer.


Eligibility criteria: Inclusion Criteria:

1. pathologically diagnosed gastric adenocarcinoma
2. Type II and III esophageal-gastric-junction malignancy
3. AJCC stage II-III
4. No contraindications for surgery, radical resection can be expected
5. KPS\>60; ECOG score:0-2
6. Expactant survival period\>6 months
7. Age 20\~75
8. No other major health issues
9. Lab results within 7 days before inclusion must satisfy:

   1. neutrophil≥1.5×109/L
   2. PLT≥100×109/L
   3. hemogloblin≥90g/L
   4. ALT,AST\<1.5 upper limit
   5. Tbil≤1.0×UNL
   6. serum creatinine\<1.5×UNL
   7. PT-INR/PTT\<1.7 upper limit
10. with measurable lesion according to RECIST1.1 criteria
11. with consent
12. co-operative

Exclusion Criteria:

1. with other major health issue
2. allergic to relevant drugs
3. experienced any other drug therapy with 4 weeks before inclusion
4. experienced any drug therapy for gastric cancer at anytime
5. diagnosed with any other malignancy within the past 5 years
6. women at child-bearing age; pregnant or breast-feeding women
7. with severe heart disease
8. with upper GI digestion or disrupted absorption
9. with peripheral neural disease
10. with transplated organs or organs having been resected for transplantation
11. known DPD deficiency
12. with uncontrolled infection

Primary outcomes:
measure: DFS
timeFrame: 3-year
Secondary outcomes:
measure: ORR
timeFrame: 3-year
measure: OS
timeFrame: 3-year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Zhongtao Zhang
state: Beijing
Study officials:
affiliation: Beijing Friendship Hospital
name: Wei Deng
role: STUDY_DIRECTOR
References:
Clinical trial NCT02649257: Influence of an Capsular Tension Ring on the Rotation of an Intraocular Lens (Aspira®-aA Also Known as MC 6125 AS)
Official title: Influence of an Capsular Tension Ring on the Rotation of an Intraocular Lens (Aspira®-aA Also Known as MC 6125 AS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Keywords: IOL rotation
capsular tension ring
IOL rotational stability
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2016-01-07
Enrollment: 100
Sex: ALL
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to observe the axial IOL rotation after surgery with a capsular tension ring (CTR) and a MC6125 AS IOL.

At the end of surgery the orientation of the IOL is documented with a short video clip via the operating microscope unit. Follow-up examinations are performed 1 hour, 1 week and 6 months after surgery. Rotational stability of the IOL is assessed using retroillumination images with a method to avoid bias from cyclorotation or head tilt.


Eligibility criteria: Inclusion Criteria:

* Uni or bilateral age-related cataract necessitating phacoemulsification extraction and posterior IOL implantation

Exclusion Criteria:

* Preceding ocular surgery or trauma
* Recurrent intraocular inflammation of unknown etiology
* Uncontrolled glaucoma
* Uncontrolled systemic or ocular disease
* Blind fellow eye
* Microphthalmus
* Corneal abnormality
* History of uveitis/iritis
* Iris neovascularization
* Pseudoexfoliation
* Proliferative diabetic retinopathy

Primary outcomes:
measure: IOL rotation
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Ophthalmology and Optometry of the Medical University Vienna
state: Vianne
Study officials:
References:
Clinical trial NCT00682357: Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis
Official title: Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis
Keywords: Osteoarthritis, intra articular steroids
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2008-05-22
Enrollment: 25
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Oral and nasal steroids may enhance osteoporosis by suppressing bone formation. Intra-articular steroids may also suppress bone formation, however, the duration or relationship to a steroid dose has not been established. It is hypothesized that intra-articular steroids suppress bone formation transiently, returning to pretreatment levels within four weeks in subjects with osteoarthritis.

Detailed description: Oral and nasal steroids may enhance osteoporosis by suppressing bone formation. Intra-articular steroids may also suppress bone formation, however, the duration or relationship to a steroid dose has not been established. It is hypothesized that intra-articular steroids suppress bone formation transiently, returning to pretreatment levels within four weeks in subjects with osteoarthritis. The purpose of the study is to determine if intra-articular steroids suppress markers of bone formation or resorption in osteoarthritis patients and whether these markers may be modified by Vitamin D or Dual-energy X-ray absorptiometry (DEXA) bone density status

Eligibility criteria: Inclusion Criteria:

* Age \> 40 years
* Male or postmenopausal female
* Diagnosis of knee osteoarthritis
* DEXA bone density done within the past 12 months
* Painful knee, visual analogue scale (VAS) \> 4 of (10=worst)

Exclusion Criteria:

* Diabetes Mellitus Type I or II
* Systemic inflammatory illness
* Systemic infections which may be aggravated by steroid therapy
* No current or previous (\< 3 years) biphosphate therapy
* Previous knee replacement surgery
* No current or previous Parathyroid hormone (PTH) therapy

Primary outcomes:
measure: Change in Serum Osteocalcin
timeFrame: Change from Baseline Visit to Day 28
measure: Change in Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)
timeFrame: Change from Baseline Visit to Day 28
Secondary outcomes:
measure: Change in Testosterone
timeFrame: Change from Baseline Visit to Day 28
measure: Change in Serum Cortisol
timeFrame: Change from Baseline Visit to Day 28
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
Study officials:
affiliation: University of Kansas Medical Center
name: Herbert Lindsley, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05890157: Treatment Of Shallow Periodontal Pockets Using PRF As an Adjunct To Scaling And Root Planing In Periodontitis Patients
Official title: Treatment Of Shallow Periodontal Pockets Using PRF As an Adjunct To Scaling And Root Planing In Periodontitis Patients, Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Periodontitis
Lead sponsor: University of Baghdad
Sponsor class: OTHER
First posted: 2023-06-06
Enrollment: 12
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Platelet rich fibrin (PRF) has been widely used in regenerative dentistry since it provides plenty amount of growth factors that enhance wound healing and tissue regeneration. Platelet derived growth factor-BB (PDGF-BB) is a growth factor with essential functions such as regulation of cell migration, proliferation, and differentiation. This study aims to evaluate the efficacy of PRF in improving the clinical periodontal parameters and GCF level of PDGF-BB.

Detailed description: Split mouth randomized clinical trial is the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets will be designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites were treated by scaling and root planing only. Clinal periodontal parameters were recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.

Eligibility criteria: Inclusion Criteria:

•periodontitis

Exclusion Criteria:

* Periodontal therapy for the last 3 months
* Medical history of systemic diseases such as diabetes.
* Patients wearing dental prosthesis
* Alcoholic patients
* Teeth with grade II mobility, endodontic lesions, and teeth with untreated caries

Primary outcomes:
measure: Change in Clinical attachment level
timeFrame: Change from baseline to 1-month and change from baseline to 3-month
measure: Change in Periodontal pocket depth measured in mm
timeFrame: Change from baseline to 1-month and change from baseline to 3-month
Secondary outcomes:
measure: Change in plaque index
timeFrame: Change from baseline to 1-month and change from baseline to 3-month
measure: Change in bleeding on probing percentage
timeFrame: Change from baseline to 1-month and change from baseline to 3-month
measure: Change in GCF level of platelet derived growth factor
timeFrame: Change from baseline to 1-month and change from baseline to 3-month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01841957: Immediate Simultaneous Bilateral Cataract Surgery
Official title: Immediate Simultaneous Bilateral Cataract Surgery: A Prospective, Case-controlled Clinical Trial in the United States
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bilateral Cataract
Keywords: Bilateral Cataract
Simultaneous Cataract Surgery
ISBCS
Lead sponsor: Panhandle Eye Group, LLP
Sponsor class: OTHER
First posted: 2013-04-29
Enrollment: 100
Sex: ALL
Minimum age (years): 30
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of treating visually significant bilateral cataract with the newer technique of Immediate Simultaneous Bilateral Cataract Surgery (ISBCS) versus the conventional technique of Delayed Sequential Bilateral Cataract Surgery (DSBCS) in a select patient population.


Eligibility criteria: Inclusion Criteria:

* Age 30-100
* Candidate for topical anesthesia
* Signed the informed consents

Exclusion Criteria:

* Allergies to medications used in study
* Cannot have topical anesthesia
* Unwilling to participate in research trial
* Have any other significant ocular comorbidities
* Have known systemic immuno-compromised state

Primary outcomes:
measure: Visual acuity
timeFrame: 3 weeks
Secondary outcomes:
measure: Recovery time and number of post-operative visits
timeFrame: 6 months
Other outcomes:
Locations:
city: Amarillo
country: United States
facility: Panhandle Eye Group
state: Texas
Study officials:
References:
Clinical trial NCT04163757: The Effects of Crocin Supplementation on Metabolic Parameters, Oxidative Stress, AMP- Activated Protein Kinase and Inflammation-promoting Genes Expression in Peripheral Blood Mononuclear Cells in Patients With Type 2 Diabetes
Official title: The Effects of Crocin Supplementation on Metabolic Parameters, Oxidative Stress, AMP- Activated Protein Kinase and Inflammation-promoting Genes Expression in Peripheral Blood Mononuclear Cells in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: National Nutrition and Food Technology Institute
Sponsor class: OTHER
Collaborators: name: Vahideh Behrouz
name: Ali Dastkhosh
First posted: 2019-11-15
Enrollment: 50
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To study the effects of crocin supplement in patients with type 2 diabetes, 50 patients will be randomly allocated to placebo group and 2 tablets of crocin for 12 weeks. At the first and the end of the intervention, lipid profiles, blood pressure, blood sugar, inflammatory and anthropometric factors will be assessed and compared between groups.


Eligibility criteria: Inclusion Criteria:

Age of 40 to 65 years type 2 diabetes: and body mass index range of 18.5 to 30 kg/m2

Exclusion Criteria:

pregnancy or lactation A history of Cardiovascular disease, Pulmonary disease, Renal disease

Primary outcomes:
measure: type 2 diabetes
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: National Nutrition and Food Technology Research Institute
Study officials:
References:
citation: Behrouz V, Dastkhosh A, Hedayati M, Sedaghat M, Sharafkhah M, Sohrab G. The effect of crocin supplementation on glycemic control, insulin resistance and active AMPK levels in patients with type 2 diabetes: a pilot study. Diabetol Metab Syndr. 2020 Jul 9;12:59. doi: 10.1186/s13098-020-00568-6. eCollection 2020.
Clinical trial NCT04019457: Cereals and Intestinal Function
Official title: Cereals and Intestinal Function: Investigations in Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endotoxemia
Diet, Healthy
Lead sponsor: University of Vienna
Sponsor class: OTHER
First posted: 2019-07-15
Enrollment: 17
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the present study is to determine the effect of dietary fiber on intestinal function in healthy subjects.

Detailed description: In the intervention study normal weight participants will receive defined amounts of different cereal flakes for several days. Before and after intervention parameters of intestinal function will be assessed.

Eligibility criteria: Inclusion Criteria:

* BMI \<25 kg/m2
* daily alcohol consumption \<20g (men) or \<10g (women)

Exclusion Criteria:

* food allergies or intolerances
* instable body weight
* BMI \<18,5 kg/m2 or \>25 kg/m2
* bariatric surgery within the last 5 years
* intake of antibiotics within the last month or during the study
* daily alcohol consumption \>20g (men) or \>10g (women)
* pregnancy and/or lactation period
* viral or bacterial infection during the last three weeks
* increased inflammatory markers of unknown reason
* chronic or acute disease of gastrointestinal tract

Primary outcomes:
measure: Changes in parameters of intestinal barrier function
timeFrame: 1 week
Secondary outcomes:
measure: Changes in blood lipid levels
timeFrame: 1 week
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: University of Vienna
Study officials:
References:
Clinical trial NCT00292357: Local Application of Autologous Bone Marrow Cells for Treatment of Chronic Diabetic Ulcers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Diabetic Foot
Diabetes Complications
Lead sponsor: Heidelberg University
Sponsor class: OTHER
First posted: 2006-02-15
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Bone marrow cells were previously shown to enhance wound healing in experimental diabetes. In this pilot study, patients with chronic diabetic ulcers not healing under conventional therapy, will be treated with local application of autologous bone marrow cells.


Eligibility criteria: Inclusion Criteria:

* Diabetes mellitus
* chronic non-healing foot ulcers (\>4weeks)

Exclusion Criteria:

* Charcot foot
* Non-diabetic ulcers
* Ulcers healing under conventional therapy
* Sepsis
* Hematologic disorders
* Pregnancy
* Acute inflammatory disorders
* Chemotherapy

Primary outcomes:
measure: Safety and Feasibility
measure: Healing velocity
Secondary outcomes:
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Medizinische Klinik 1, Universitätsklinikum Heidelberg
Study officials:
affiliation: University of Heidelberg, Dept. Medicine 1, Germany
name: Peter Nawroth, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06931457: Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet Rich Plasma to Treat Idiopathic Glossopharyngeal Neuralgia (GPN)
Official title: Efficacy and Safety of the Application of Pulsed Radiofrequency, Combined With Platelet Rich Plasma, to the Treatment of Idiopathic Glossopharyngeal Neuralgia (GPN): A Study Protocol for a Multi-Center, Prospective, Open-Label, Propensity Score Match Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Glossopharyngeal Neuralgia
Pulsed Radiofrequency
Platelet Rich Plasma
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
First posted: 2025-04-17
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Suitable participants will be screened at the pain management center of each hospital to participate in the study.

Brief summary: To investigate the efficacy and safety of the application of PRF combined PRP to the for the treatment of GPN.


Eligibility criteria: Inclusion Criteria:

1. age \>18 years;
2. diagnosed with idiopathic GPN according to the third International Classification of Headache Disorders (ICHD) classification;
3. patients who failed pharmacotherapy or intolerable side effects of medication;
4. undergoing PRF for GPN;
5. at least 1 month of follow-up recordings.

Exclusion Criteria:

1. Patients with bilateral GPN;
2. Abnormalities in blood measurements, liver and kidney function, blood glucose, coagulation, electrocardiography or chest radiography;
3. Infection at the puncture site;
4. Previous mental illness;
5. Previous history of narcotic drug abuse;
6. Prior anticoagulant or antiplatelet therapy;
7. An implantable pulse generator;
8. Current pregnancy or breast feeding.
9. Patients with incomplete medical records (lack of baseline data or postoperative follow-up data).

Primary outcomes:
measure: Numeric rating scale (NRS) score
timeFrame: 1day, 3days, 1week, 2weeks, 1month, 3months, 6months, and 1year following the procedure
Secondary outcomes:
measure: Barrow Neurological Institute pain scale(BNI score)
timeFrame: 1day, 3days, 1week, 2weeks, 1month, 3months, 6months, and 1year following the procedure
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital
state: Beijing
Study officials:
References: